ReviewFrontiers in cellular and infection microbiology2023
Unveiling the stealthy tactics: mycoplasma's immune evasion strategies.
Review in Frontiers in cellular and infection microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Genital mycoplasma infections: a hidden factor in cervical cancer progression? A systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- Mycoplasma pneumoniae infections in the Post-COVID era: recent advances from pathogenesis to clinical management.Infection · 2026Review
- Host specificity and horizontal gene transfer in the MIB-MIP immunoglobulin evasion system in Mycoplasma gallisepticum.Veterinary research · 2026Article
- Melatonin attenuates Mycoplasma pneumoniae-Induced Inflammation and barrier dysfunction by CXCL10/TLR4/STAT1 axis.Cell communication and signaling : CCS · 2026Article
- Distinct host-pathogen and microbiome responses of aoudad (Ammotragus lervia) and bighorn sheep (Ovis canadensis) following exposure to Mycoplasma ovipneumoniae with or without co-exposure to leukotoxigenic Pasteurellaceae.BMC veterinary research · 2026Article
- Clinical Presentation, Detection, and Immunopathogenesis ofPathogens (Basel, Switzerland) · 2026Article
- Evaluation of risk factors and treatment options associated with extra-urogenitalFrontiers in medicine · 2026Article
- Nuclear IL-33 amplifies NF-κB signaling to drive neutrophil recruitment and activation in the endocervical epithelium duringFrontiers in immunology · 2026Article
- No Effect in Plasma Corticosterone Levels After Observation of Diseased Conspecifics.Integrative organismal biology (Oxford, England) · 2026Article
- Drug resistance ofFrontiers in cellular and infection microbiology · 2026Review
- Doxycycline for Macrolide-ResistantInfection and drug resistance · 2026Review
- The predictive accuracy of systemic immune-inflammation index and lymphocyte-to-monocyte ratio for extrapulmonary complications in pediatricTranslational pediatrics · 2025Article
- Serological evidence and risk factors ofOpen veterinary journal · 2025Article
- An immunoinformatics-based designed multi-epitope candidate vaccine against Mycoplasma pneumoniae.BMC microbiology · 2025Article
- Development of human mycoplasma vaccines: navigating the IL-17A paradox.Frontiers in immunology · 2025Review
- Chinese advances in understanding and managing genitourinary tract infections caused by Mycoplasma genitalium, Mycoplasma hominis, and Ureaplasma urealyticum.Archives of microbiology · 2024Review
- Association between 25-hydroxy vitamin D, interleukin-4, and interferon-γ levels and asthma in children with Mycoplasma pneumonia infection.Scientific reports · 2024Article
- Antagonistic Effects of Actin-Specific Toxins onBiomolecules · 2024Article
- Advancements in Green Nanoparticle Technology: Focusing on the Treatment of Clinical Phytopathogens.Biomolecules · 2024Review
- Research Progress on Immune Evasion ofMicroorganisms · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mycoplasmas, the smallest known self-replicating organisms, possess a simple structure, lack a cell wall, and have limited metabolic pathways. They are responsible for causing acute or chronic infections in humans and animals, with a significant number of species exhibiting pathogenicity. Although the innate and adaptive immune responses can effectively combat this pathogen, mycoplasmas are capable of persisting in the host, indicating that the immune system fails to eliminate them completely. Recent studies have shed light on the intricate and sophisticated defense mechanisms developed by mycoplasmas during their long-term co-evolution with the host. These evasion strategies encompass various tactics, including invasion, biofilm formation, and modulation of immune responses, such as inhibition of immune cell activity, suppression of immune cell function, and resistance against immune molecules. Additionally, antigen variation and molecular mimicry are also crucial immune evasion strategies. This review comprehensively summarizes the evasion mechanisms employed by mycoplasmas, providing valuable insights into the pathogenesis of mycoplasma infections.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.